Development of GPIIb/IIIa antagonists as antithrombotic drugs.
Thrombosis represents a major target for development of drugs to prevent and treat a variety of cardiovascular and cerebrovascular diseases, which are the leading cause of morbidity and mortality in the Western world. This review by Andy Nichols and colleagues focuses on a central process in thrombosis, namely platelet aggregation, and how it can be inhibited by antagonists of the adhesion molecule GPIIb/IIIa. Successful and future therapeutic applications of GPIIb/IIIa antagonists, and their pharmacology, are considered in detail.
Nichols
A J
AJ
Smith-Kline Beecham Pharmaceuticals, King of Prussia, PA 19406.
Ruffolo
R R
RR
Huffman
W F
WF
Poste
G
G
Samanen
J
J
D000595:Amino Acid Sequence; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000494:pharmacology / Q000502:physiology; D010974:Platelet Aggregation / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*
D005343:Fibrinolytic Agents; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; C047981:arginyl-glycyl-aspartic acid